The validation of the Hungarian version of the ID-migraine questionnaire

Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.

show abstract

“…23 ). Both instruments have been translated and validated for use in several languages [24][25][26][27] .…”

Section: Diagnostic Aidsmentioning

confidence: 99%

Diagnosis and management of migraine in ten steps

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This novel hybrid questionnaire instrument, in two parts, was developed to avoid issues noted with other investigative scales. Many traditional measurements are perceived as too lengthy, requiring frequent re-ratings, prolonged survey time, which generally adds a measurement bias and lower compliance, and may use scoring criteria which may be difficult for the subject to understand [46][47][48][49]. The Colorado Center for Health and Sports Science Institutional Review Board (CCHSS IRB) reviewed the applicants, with forty (N=40) subjects being accepted into and completing the study.…”

Section: Methodsmentioning

confidence: 99%

A unique medium chain triglyceride-containing micronutrient complex: Effects on migraine symptoms compared to quality of lif

Wolkodoff¹,

Haase²,

Kapteyn³

2022

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Purpose: Migraine headaches and associated symptoms are prevalent medical issues. Medium-chain triglyceride (MCT)/nootropic-based compounds have demonstrated benefits in multiple domains. This study assessed the potential relief provided from a unique, high-concentration MCT/nootropic component blend on migraine frequency, duration, secondary symptoms, and quality of life (QOL) during a 60-day clinical investigation. Methods: Forty (n=40) chronic migraine sufferers [migraineurs] were prospectively randomized to participate in the double-blinded study. Both intervention (n=30) and control (n=10) participants were required to maintain lifestyle patterns for the trial duration. Migraine surveys used electronic response forms to allow subjects increased ease and safety during the COVID-19 pandemic. Results. The intervention subjects experienced reduction in migraine episodes by 53%, from 11.6 to 5.4 per month, after 60 days of supplement use. The average episode duration decreased from 260 minutes to 158 minutes, a 39% improvement. Time lost due to severe migraine effect was reduced from an average of more than five days per month to just over two per month, a decrease of 55%. A combined measure of secondary symptoms, which aggregate to illustrate migraine intensity, also decreased according to subject rating by an average of 37%. Self-assessed QOL scales improved by 43% in the intervention cohort. The control subjects showed no significant changes in any measures. Conclusion: Consumption of a unique, nootropic brain complex significantly improved migraine symptoms, including episode frequency, duration, severity, and lost days due to dysfunction. The formulation also beneficially impacted secondary effects and self-reported QOL.

show abstract

“…This novel hybrid instrument was developed to avoid common problems noted with other scales. These issues include being too lengthy, requiring responses too frequently, prolonged study periods leading to recall bias and lowered compliance, as well as proprietary forms that required payment for use [36][37][38][39]. Subject applicants were then reviewed and approved by the Colorado Center for Health and Sports Science Institutional Review Board (CCHSS IRB), with fourteen (N=14) subjects being accepted into and completing the study.…”

Section: Methodsmentioning

confidence: 99%

The effects of a unique medium chain triglyceride complex on migraine symptoms: A beta pilot study

Wolkodoff¹,

Haase²,

Firger³

2020

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Purpose: Migraine headaches are among the most common worldwide medical issues, and various drug therapies only offer limited relief. Medium chain triglyceride (MCT) oil has demonstrated clinical benefits in multiple domains, from enhanced overall energy to increased brain function. This pilot study investigated the potential relief provided from a unique proprietary formulation, including a high concentration MCT-containing blend on migraine frequency, duration, and severity over 30 days. Methods: Fourteen (n=14) chronic migraine sufferers (migraineurs) were prospectively selected to participate in the open-label trial of this patented complex. Participants were instructed to maintain a consistent lifestyle, health factors, and medications while consuming the study compound. Because of the current Corona virus pandemic, the original paper version of the migraine survey was converted to an electronic response form to allow subjects increased safety in rating episodes and symptoms. Results: Overall, the subjects reduced the number of migraine episodes by 39% from the baseline period compared to after 30 days of using the supplement. The average episode duration decreased from 388 minutes to 152 minutes, a 61% reduction. Days/events missed due to migraine severity or complications were reduced from five per month to two per month, a decrease of 60%. A combined measure of specific symptoms also decreased according to subject rating, by an average of 32%. Conclusion: In this beta pilot study, consumption of a high concentration MCT complex produced significant improvements in migraine symptoms in the three significant episode realms of frequency, duration, and lost days due to dysfunction. In addition, migraine symptom surveys can be converted to electronic record keeping, a benefit for both the patient and the clinician. These outcomes have provided further impetus to pursue a rigorous study of specific MCT products to reduce migraine symptoms. A formal confirmatory placebo-controlled trial has been initiated.

show abstract

The validation of the Hungarian version of the ID-migraine questionnaire

Cited by 12 publications

References 42 publications

Diagnosis and management of migraine in ten steps

Diagnosis and management of migraine in ten steps

A unique medium chain triglyceride-containing micronutrient complex: Effects on migraine symptoms compared to quality of lif

The effects of a unique medium chain triglyceride complex on migraine symptoms: A beta pilot study

Contact Info

Product

Resources

About